Skip to main content

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology

University of Milano

Director, Laboratory for the Study of Lipoproteins and Atherosclerosis

Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis

Bassini Hospital

Director, Center of Epidemiology and Preventive Pharmacology

University of Milano (SEFAP)

Immediate Past President, European Atherosclerosis Society (EAS)

Milan, Italy

Related Videos

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

What specific LDL-C-related endpoints are likely to undergo review and revisions based on the publication of two PCSK9-related trials, ODYSSEY Outcomes and FOURIER?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

How are your 2019 ESC/EAS guidelines going to be influenced by recent RCTs, including ODYSSEY Outcomes and FOURIER?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

Where did the 70 mg/dL LDL-C target goal come from? Why wasn’t it set lower in the guidelines from the outset for patients with ACS?

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

Given what we know about the safety of PCSK9 inhibitors and the risk of recurrent events in patients who have experienced an ACS,

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance?

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

In patients requiring down-titration of their statins due to muscle discomfort/pain, what is the trigger point for moving beyond statins to consider PCSK9 inhibitors?

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?

Which patient subgroups that, based on the Odyssey Outcomes Trial, could benefit significantly from a PCSK9 inhibitor, in your observation, are not getting treatment consistently enough—i.e. are being “under-treated”—with these agents?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?

From the perspective of a lipid and atherosclerosis specialist, assuming that the barriers to PCSK9 inhibitors are reduced, which patients at risk for—or with confirmed—ASCVD represent the best, risk-directed candidates for LDL-C lowering?